Description: MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Home Page: meiragtx.com
450 East 29th Street
New York,
NY
10016
United States
Phone:
646 860 7985
Officers
| Name | Title |
|---|---|
| Dr. Alexandria Forbes Ph.D. | CEO, President & Director |
| Mr. Richard Brian Giroux B.A. | COO & CFO |
| Dr. Stuart Naylor Ph.D. | Chief Development Officer |
| Mr. Robert J. Wollin J.D. | General Counsel & Secretary |
| Dr. Michel Michaelides M.D. | Head of Clinical Ophthalmology |
| Ms. Christine Elise Sheehy | Senior Vice President of Global Integration |
| Mr. Tim Randall | Senior Vice President of Risk & Internal Controls |
| Dr. Alastair Leighton Ph.D. | Senior Vice President of Manufacturing & Supply Chain |
| Dr. Robert K. Zeldin M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 2.0513 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.8391 |
| Price-to-Sales TTM: | 55.1054 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 387 |